Malignant optic nerve glioma in a young woman with 7 year follow up without recurrence

Chris R. Alabiad a,⁎, Veeral S. Shah b, Tiffany A. Eatz a, Linda L. Sternau c, Byron L. Lam a

a Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, 900 NW 7th Street Miami, FL, 33136, United States
b Department of Ophthalmology, University of Cincinnati, 3333 Burnet Ave, Cincinnati, OH, 45229, United States
c Private Practice Neurosurgeon, 1150 N 35th Ave Ste 300, Hollywood, FL, 33021, United States

ARTICLE INFO

Keywords:
Malignant optic nerve glioma
Temozolomide
Neovascularization of the optic nerve
Remission
Radiation

ABSTRACT

Purpose: To report diagnostic and management challenges of a case of WHO Grade III glioma of the optic nerve occurring in an unusually young patient with more than 7 years of survival without recurrence.

Observations: An 18-year-old woman reported rapidly progressive vision loss in the right eye in the setting of a right optic nerve lesion, central retinal artery occlusion, central retinal vein occlusion, and neovascularization of the optic disc. An orbital MRI with contrast demonstrated enhancement of the intraocular, intraorbital, and intracanalicular portion of the right optic nerve. Biopsy of a portion of the intraorbital optic nerve was negative, however, biopsy of the intracranial optic nerve confirmed WHO Grade III glioma (anaplastic astrocytoma). Although the tumor was excised, there remained positive margins at the optic chiasm. The patient was then managed with a combination of radiation and temozolomide. Postoperatively, the initial neovascularization of the optic nerve that had resolved, re-emerged with gliosis. In this setting a concern for intraorbital tumor arose and the globe was enucleated, definitively ruling out neoplasm. The patient has remained tumor free seven years after resection.

Conclusions and importance: Malignant optic pathway glioma is rare and carries a high 5-year mortality rate. Diagnosis can be elusive given orbital MRI with contrast often appears to be non-specific. Inflammatory changes can be confounding such that a biopsy in the respective area will yield a negative pathologic result. Repeat biopsy is recommended if clinical suspicion is high. Combination treatment of optic nerve tumor resection, temozolomide and radiation has been effective in treating this patient who continues to be followed closely and has had no clinical or radiographic evidence of recurrence in over 7 years. The re-emergence of neovascularization with gliosis/fibrosis of the optic nerve, was driven by ischemia and further precipitated by radiation. To our knowledge this patient represents the youngest reported case of malignant optic nerve glioma with the longest reported survival in the literature to date (over seven years).

1. Introduction

Malignant optic pathway gliomas in adults were first described in 1973 by Hoyt.1 Since then over 70 cases have been reported in the literature.2–4 These tumors represent approximately one percent of all intracranial gliomas and affect women and men in a fairly equal distribution. Mean onset is in the sixth decade of life with the youngest case reported being age 22 years.3,4 Malignant optic pathway gliomas arise de novo from astrocytes within the optic nerve, the optic chiasm, or optic tracts and are quite challenging to diagnose and treat. Patients typically present with rapidly progressive unilateral vision loss of unclear etiology. Their clinical and radiologic features can mimic common entities such as optic neuritis, neurosarcoidosis, optic neuropathy, or retinal vascular occlusion, further delaying diagnosis and proper treatment of this condition. MRI findings include thickening of the optic nerve with contrast enhancement on T1-weighted images; however, T2-weighted signal changes are relatively heterogeneous without a consistent pattern. Tissue biopsy is critical to confirm the diagnosis. The World Health Organization (WHO) classifies these malignant lesions according to their pathologic appearance, which include anaplastic astrocytomas (WHO grade III) and glioblastoma multiforme (WHO grade IV). Management includes surgical resection, chemotherapy, and

⁎ Corresponding author. Professor of Ophthalmology, University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute, 900 NW 7th Street, Miami, FL, 33136, United States.

E-mail address: calabiad@med.miami.edu (C.R. Alabiad).

https://doi.org/10.1016/j.ajoc.2020.100862
Received 16 April 2020; Received in revised form 8 July 2020; Accepted 3 August 2020
Available online 11 August 2020
2451-9936/© 2020 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
radiation. Despite treatment, the mortality rate is extremely high with death usually within 1 year and the longest reported survival of 20 months.\textsuperscript{2–4}

We share a challenging case of an 18-year-old woman who presented with vision loss in the setting of a WHO grade III optic pathway glioma. She remains tumor free seven years after optic nerve tumor resection, chemotherapy, and radiation. To our knowledge this patient represents the youngest reported case of malignant optic pathway glioma and the longest reported survival in the literature to date.

2. Case report

An 18-year-old woman with no significant past medical history presented to the neuro-ophthalmology clinic for a second opinion to evaluate rapidly progressive vision loss in her right eye. Symptoms began 3 months prior with difficulty focusing and photophobia in the affected eye. These symptoms progressed to complete vision loss within one month of their onset. Her cerebrospinal fluid and serologic evaluation at the time was exhaustive and inconclusive. Serum Epstein Barr IgG was elevated. Pertinent negative labs included ACE, ANA, Toxoplasmosis IgG, and NMO antibodies. MRI of the orbits showed enhancement of the intraocular, intraorbital and intracanalicular right optic nerve extending to the right chiasm without significant T2 hyperintensity (Fig. 1). She was treated with multiple courses of IV and oral steroids without effect.

Examination confirmed NLP vision in the right eye with an anamnestic pupil. A pale, infiltrated, edematous right optic nerve was evident with neovascularization of the optic disc and absence of perfusion of the central retinal artery and vein (Fig. 2). Examination of the left eye was normal. A right optic nerve biopsy was performed through a transconjunctival orbitotomy, and pathology disclosed inflammation. Given high suspicion for malignancy, the intracranial optic nerve was biopsied through a superior craniotomy yielding a diagnosis of anaplastic astrocytoma (WHO Grade III). Globe sparing resection of the optic nerve was then undertaken using the technique described by Shriver et al.\textsuperscript{7} Tumor was identified in the intracranial and intracanalicular portions of the optic nerve (Fig. 3), but not intraorbital. Posterior margins at the level of the anterior optic chiasm were positive for malignant astrocytoma.

The patient underwent chemotherapy (6 month course of temozolomide) and radiation (60 Gray in 30 fractions). Serial examinations showed regression of neovascularization of the right optic nerve at postoperative month 3 (Fig. 4A) and postoperative month 6 (Fig. 4B) visits and MRI confirmed absence of disease. One year after surgical resection, the patient presented with intraocular optic nerve thickening and new hemorrhage at the level of the intracanalicular optic nerve (Fig. 4C). In light of concern for intraocular malignancy, the globe was enucleated. Review of pathology did not reveal intraocular tumor. The fornix was then rehabilitated with an ocular prosthesis. The patient has been followed clinically and with serial MRIs of the orbit (Fig. 5) for seven years without evidence of disease recurrence and with 20/20 vision and a full field of vision in her contralateral eye.

3. Discussion

This youngest reported case of malignant optic pathway glioma with the longest reported survival highlights unique challenges of the disease process. In line with previously reported cases of malignant optic pathway gliomas, this patient presented with painless, subacute, unilateral vision loss, accompanied by an extensive, non-revealing serologic work up and neuroimaging that appeared consistent with a myriad of optic nerve pathologies, including but not limited to infectious, inflammatory, and neoplastic causes. Her initial treatment was also similar to previous reports in that a presumptive inflammatory optic nerve process was managed using steroid. Given the lack of response and findings on the MRI, an intraorbital approach to the optic nerve biopsy was deemed appropriate. Gross examination of the optic nerve intraoperatively was notable for black grainy material encasing the nerve within the optic nerve sheath, suggestive of a distant hemorrhagic event. The biopsy of this lesion only showed mild inflammation which was perplexing. Though a cause for a negative biopsy may result from a biopsy that includes only the dural sheath, the biopsy specimen contained optic nerve tissue. Given a raised index of suspicion, an intracranial

Fig. 1. Sequential axial T1 weighted, fat saturated MRI with gadolinium images (A–C) on presentation demonstrating enhancement of the intraocular, intraorbital and intracanalicular right optic nerve extending toward the right chiasm.

Fig. 2. Right optic nerve upon presentation showing optic nerve edema, pallor, neovascularization, central retinal artery occlusion and central retinal vein occlusion, hyalinization of vessels, and cotton wool spots.
biopsy was performed allowing for the diagnosis of a WHO grade III optic pathway glioma. Indeed, the importance of pursuing a re-biopsy diagnosing malignant optic nerve glioma to establish a definitive diagnosis cannot be overemphasized.

Resection of the intraorbital, intracanalicular, and prechiasmal optic nerve also confirmed that there was no tumor in the intraorbital portion of the optic nerve. Intralesional hemorrhage within optic pathway gliomas, though rare, has been reported in WHO grade I and II lesions;8–12 and less so in WHO grade III and IV lesions. This is in contrast to malignant gliomas in other locations which are known to hemorrhage as the tumors outgrow their blood supply and necrose or invade into a vessel. An intralesional bleed within the intracranial portion of the optic nerve, extending within the dural sheath of the intraorbital portion of the optic nerve may explain the preoperative MRI findings (diffuse enhancement and thickening of the optic nerve on T1 images with gadolinium) and the clinical findings of optic nerve head thickening, central retinal artery occlusion and central retinal vein occlusion.

Review of the permanent slides of the tumor pathology revealed anaplastic astrocytoma (WHO grade III) with positive microscopic margins at the posterior margins of the resection at the level of the anterior optic chiasm. This was in contrast to the clear margins obtained during intraoperative frozen section analysis. The Ki67 index at the posterior margin was 4–5%, suggesting a low mitotic rate. Ki-67, a nuclear antigen expressed during proliferative phases of the cell cycle, is useful in understanding the biologic behavior of tumors.13 In patients 18 years and younger with low grade gliomas, cause specific survival was significantly higher in patients with an average Ki-67 index less than 5%.14

---

Fig. 3. Hematoxylin and Eosin staining of initial intraorbital optic nerve biopsy specimen (A) showing lymphocytes consistent with chronic inflammation. Hematoxylin and Eosin staining of the intracranial optic nerve from subsequent craniotomy (B) demonstrates tumor consistent with anaplastic astrocytoma (WHO grade III) and Ki67 staining (C) showed an index of 4–5% at the chiasmal margin.

Fig. 4. Optic nerve photos 3 months (A) and 6 months (B) after tumor resection showing regression of the neovascularization of the disc and glial fibrosis at the optic nerve head. The photo 12 months post resection (C) demonstrates the reappearance of neovascularization at the optic nerve head with more prominent fibrosis.

Fig. 5. Post-operative sequential axial T1 weighted, fat saturated MRI with gadolinium images (A,B) showing a right orbital implant and absence of disease at the level of the chiasm 7 years after surgical resection, chemotherapy, and radiation.
Until recently, the mainstay of treatment after surgical resection of intracranial malignant gliomas is 54–60 Gray radiation to the surgical bed. The discovery of temozolomide, an oral alkylating agent found to have efficacy against malignant gliomas,15–18 has provided a very effective therapy for malignant gliomas. The addition of temozolomide to radiation further potentiates tumoricidal activity in-vivo19 leading to increased survival in-vivo20 in patients with glioblastoma multiforme (WHO Grade IV). Two year survival rates were 26.5% in the combined temozolomide and radiation group compared to 10.4% in the radiation alone group.

Several considerations were taken in determining the next step in management of our patient. Further resection would address residual tumor but would be associated with the morbidity of repeat intracranial surgery and the likelihood of permanent vision loss in the patient’s only seeing eye as the resection encroaches on the optic chiasm. The low Ki-67 index in the microscopic positive margin prompted the team to proceed with temozolomide and radiation with plan for close monitoring.

The patient did remarkably well after surgical excision with eventual resolution of neovascularization at the optic nerve head at postoperative month 6. At postoperative year 1 visit, the recurrent neovascularization at the optic nerve head and worsening gliosis raised concern for intraocular tumor involvement despite the fact that the pathology from the previous surgical resection confirmed absence of tumor at the level of the intraorbital optic nerve. Intraocular malignant glioma has been described in the literature21 (albeit without pathological confirmation) presenting with a similar appearance to our patient, including a combined central retinal artery and vein occlusion with peripapillary changes. In close consultation with the patient, enucleation was advised given the vision was no light perception in this eye. This confirmed absence of intraocular tumor and supported the theory that the neovascularization was driven by ischemia which was further potentiated by her recent radiation treatment.

4. Conclusions

This case affirms malignant optic pathway gliomas often masquerade as other entities on both clinical exam and neuroimaging, making timely diagnosis challenging. When an initial biopsy is negative, pursuit of a repeat biopsy in a different location is prudent, particularly when clinical suspicion is high. Surgical resection is best supplemented with adjuvant chemotherapy. Temozolomide plus radiation was successful in clearing a positive posterior margin in this particular tumor which had a low Ki-67 index. The re-emergence of neovascularization with gliosis/fibrosis of the optic nerve, was driven by ischemia and further precipitated by radiation. To our knowledge this patient represents the youngest reported case of malignant optic pathway glioma and the longest reported survival in the literature to date (over seven years).

Patient consent

Consent to publish the case report was not obtained. This report does not contain any personal information that could lead to the identification of the patient.

Funding

Supported by NIH Center Core Grant P30EY014801 and Research to Prevent Blindness Unrestricted Grant

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Declaration of competing interest

The following authors have no financial disclosures or personal conflicts of interest: CRA, VSS, TAE, LLS, BLL.

Acknowledgements/Disclosures

All procedures performed in this study involving a human participant adhered to the 1964 Declaration of Helsinki and its later amendments. Collection of information in this report complied with the Health Insurance Portability and Accountability Act of 1996.

Financial Support: NIH Center Core Grant P30EY014801, RPB Unrestricted Award and Career Development Awards, Department of Defense (DOD-Grant #W81XWH-09-1-0675).

References

1. Hoyt WF, Meshel LG, Lescell S, Schatz NJ, Suckling RD. Malignant optic glioma of adulthood. Brain. 1973;96(1):121–132.
2. Mastorakos P, Haus MA, Caruso JP, et al. Transtentorial dissemination of optic nerve glioblastoma: case report. J Neurosurg. 2016;126(2):406–413.
3. Traeger GL, Pangalp A, Neumann M, et al. Malignant optic glioma – the spectrum of disease in a case series. Graefes Arch Clin Exp Ophthalmol. 2015;253(7):1187–1194.
4. Wabbel B, Demmler A, Seitz J, Woernckhaus M, Blons FG, Lorentz B. Unilateral adult malignant optic nerve glioma. Graefes Arch Clin Exp Ophthalmol. 2004;242(9):741–748.
5. Miller NR. Primary tumours of the optic nerve and its sheath. Eye (Lond). 2004;18(11):1026–1037.
6. Miller WS, Tartaglino LM, Serpott RC, Friedman DP, Flanders AE. MR of malignant optic glioma of adulthood. AJNR Am J Neuroradiol. 1995;16(8):1673–1676.
7. Shriver RM, Ragheb J, Tse DT. Combined transtentorial-orbital approach for resection of optic nerve gliomas. Ophthalmic Plast Reconstr Surg. 2012;28(3):184–191.
8. Applegate LJ, Pribram HF. Hematoma of optic nerve glioma– a cause for sudden proptosis. Magnetic resonance imaging findings. J Clin Neuro Ophthalmol. 1989;9(1):15–19.
9. Charles NC, Nelson I, Brookner AR, Lieberman N, Brenim GM. Pilocytic astrocytoma of the optic nerve with hemorrhage and extreme cystic degeneration. Am J Ophthalmol. 1981;92(5):691–695.
10. Schneider RC, Kriss FC, Falls HF. Prechiasmal infarction associated with intrachiasmal and suprachiasmal tumors. J Neurosurg. 1979;50(2):197–208.
11. Maitland CO, Ahiko S, Hoyt WF, Wilson CB, Okamura T. Chiasmal apoplexy. Report of four cases. J Neurosurg. 1982;56(1):118–122.
12. van Baarssen K, Roth J, Serova N, et al. Optic pathway-pseudohypothalamic glioma hemorrhage: a series of 9 patients and review of the literature. J Neurosurg. 2018;129(4):1407–1415.
13. Patours E, Stocker U, Kallmeyer V, Keiditch E, Mehrzaei P, Stavrou D. Relationship between Ki-67 positive cells, growth rate and histological type of human intraxiallary tumors. Anticancer Res. 1989;9(4):537–544.
14. Fisher RJ, Naunova E, Leighton CC, et al. Ki-67: a prognostic factor for low-grade gliomas? Int J Radiat Oncol Biol Phys. 2002;52(4):996–1001.
15. Bower M, Newlands ES, Bleehe NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Canc Chemother Pharmacol. 1997;40(6):484–488.
16. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Canc Treat Rev. 1997;23(1):55–61.
17. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001;2(9):552–560.
18. Yung WK. Temozolomide in malignant gliomas. Semin Oncol. 2000;27(3 Suppl 6):27–34.
19. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Ant Canc Drugs. 1997;8(1):92–97.
20. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
21. Dumas-Stoeckel S, Gambrelle J, Cornut FL, El Chehab H, Vighetto A, Denis P. (Central retinal vein and artery occlusions related to intracranial involvement of an anaplastic optochiasmatic glioma). J Fr Ophtalmol. 2010;33(8):564–567.